S Marijuana Drug Stocks: All You Need To Know

This article addresses the 8 clinical-stage companies researching the treatment of a wide variety of illnesses using marijuana of which 6 have market capitalizations in excess of $50M and less than $500M and 2 have market capitalizations in excess of $37M.

(For some insight into 12 clinical-stage companies researching the treatment of a variety of mental illnesses based on the use of "magic mushrooms" (psilocybin), "magic" psilocybin truffles, ketamine, DMT, Ibogaine, LSD, MDMA, 5-MeO-DMT, and mescaline you are encouraged to read Psychedelic Stocks: Which Have The Greatest Potential?

  1. Allied Corp. (ALID): Market Cap. of $86M
    • The company is researching, creating, and producing targeted cannabinoid health solutions to help people suffering from:
      • Post-Traumatic Stress Disorder (PTSD), anxiety, and depression in addition to growing and processing the cannabis plant itself and developing a line of therapeutic CBD-based products.
    • Allied's stock price is DOWN -10.8% since the end of May but is UP 34.7% YTD
  2. Corbus Pharmaceuticals (CRBP): Market Cap. of $155M
    • The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes such as:
      • Dermatomyositis (in Phase 3) and
      • Systemic Lupus Erythematosus (in Phase 2).
    • Corbus' stock price is DOWN -42.9% since the end of May and is unchanged YTD.
  3. Enveric Biosciences (ENVB): Market Cap. of $40M
    • Enveric is endeavoring to enhance the lives of those who are adversely affected by the side effects of cancer treatments such as:
      • radiodermatitis and chemotherapy-induced peripheral neuropathy as well as the treatment of glioblastoma
    • Enveric's stock price is DOWN -19.9% since the end of May and DOWN -56.3% YTD.
  4. MGC Pharmaceuticals (MGCLF): Market Cap. of $73M
    • MGC has developed a pipeline of phytocannabinoid derived medications for the treatments of:
    • Neurology diseases such as:
      • Refractory Epilepsy, Dementia, Alzheimer’s Disease, and Cerebral Palsy.
    • Oncology related to:
      • anorexia-cachexia and glioblastoma, melanoma, and prostate cancers.
    • MGC's stock price is DOWN -25% since the end of May but is UP +50% YTD.
  5. Revive Therapeutics (RVVTF): Market Cap. of $106M
    • The company has been granted two Orphan Drug Designations by the FDA for the use of CBD:
      • in the treatment of: Autoimmune Hepatitis, and
      • in the prevention of Ischemia and Reperfusion Injury resulting from solid organ transplantation, such as liver, kidney, heart, and lungs.
    • Revive's stock price is DOWN -13.2% since the end of May and is DOWN -32.7% YTD.
  6. Tetra Bio-Pharma (TBPMF): Market Cap. of $102M
    • The Company is focused on developing cannabinoid-derived medicines for the treatment of:
      • inflammation (Cytokine Release Syndrome),
      • cancer pain (Qixleef and Caumz which are in Phase 2),
      • ophthalmology (Uveitis, and Proliferative Vitreoretinopathy which has an Orphan Drug Designation), and
      • oncology (Cancer Cachexia which is in Phase 2 and Hepatocellular Carcinoma which has an Orphan Drug Designation).
    • Tetra Bio's stock price is DOWN -19.4% since the end of May and is UP +66.7% YTD.
  7. Zelira Therapeutics (ZLDAF): Market Cap. of $73M
    • The company is:
      • testing a range of the company’s cannabinoid-based formulations and protocols in pre-clinical research for the treatment of pancreatic cancer, breast cancer, brain cancer, and diabetes-associated cognitive decline, pediatric autism, chronic pain, and chronic insomnia.
    • Zelira's stock price is DOWN -25% since the end of May and is DOWN -50% YTD.
  8. Zynerba Pharmaceuticals (ZYNE): Market Cap. of $37M
    • The company hopes to provide new treatment options for patients battling certain rare neuro-psychiatric diseases (those affecting fewer than 200K patients in the U.S.) and near-rare neuropsychiatric conditions (i.e. those affecting fewer than one million patients).
    • Its clinical pipeline consists of research into:
      • Fragile X Syndrome (FXS);
      • 22q Deletion Syndrome (22q);
      • Autism Spectrum Disorder (ASD) and
      • a heterogeneous group of rare and ultra-rare epilepsies known as Developmental & Epileptic Encephalopathies (DEE) and
      • Autoimmune conditions such as Chron's Disease, IBS, and Eczema.
    • Zynerba's stock price is DOWN -21.8% since the end of May but is UP +35.5% YTD.

Visit  munKNEE.com and register to receive our free Market Intelligence Report newsletter (sample  more

How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.